Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity

Cardiovascular Revascularization Medicine

Volumn 14, Issue 2, 2013, Pages 76-80

  Gaglia, Michael A ^a   Torguson, Rebecca ^a   Pokharel, Shreejana ^a   Pakala, Rajbabu ^a   Xue, Zhenyi ^a   Suddath, William O ^a   Kent, Kenneth M ^a   Satler, Lowell F ^a   Pichard, Augusto D ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Light transmission aggregometry; Percutaneous coronary intervention; Vasodilator stimulated phosphoprotein phosphorylation

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PRASUGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; ARTICLE; BLEEDING; CAUCASIAN; CLINICAL ARTICLE; ECCHYMOSIS; EPISTAXIS; HEMATOCRIT; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; MALE; MELENA; ORAL BLEEDING; PLATELET REACTIVITY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING;

AGED; ASPIRIN; BIOLOGICAL MARKERS; BLOOD PLATELETS; CELL ADHESION MOLECULES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHOPROTEINS; PIPERAZINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THIOPHENES; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875067152     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2012.12.005     Document Type: Article

References (32)

1. Gurbel P.A., Antonino M.J., Bliden K.P., Dichiara J., Suarez T.A., Singla A., Tantry U.S. Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. Platelets 2008, 19:595-604.
2. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., Ernst A., Sawhney N.S., Schatz R.A., Teirstein P.S. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008, 29:992-1000.
3. Bonello L., Paganelli F., Arpin-Bornet M., Auquier P., Sampol J., Dignat-George F., Barragan P., Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007, 5:1630-1636.
4. Cuisset T., Hamilos M., Sarma J., Sarno G., Wyffels E., Vanderheyden M., Barbato E., Bartunek J., De Bruyne B., Wijns W. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am J Cardiol 2008, 101:1700-1703.
5. Marcucci R., Gori A.M., Paniccia R., Giusti B., Valente S., Giglioli C., Buonamici P., Antoniucci D., Abbate R., Gensini G.F. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009, 119:237-242.
6. Breet N.J., van Werkum J.W., Bouman H.J., Kelder J.C., Ruven H.J.T., Bal E.T., Deneer V.H., Harmsze A.M., van der Heyden J.A.S., Rensing B.J.W.M., Suttorp M.J., Hackeng C.M., ten Berg J.M. Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation. JAMA 2010, 303:754-762.
7. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., Neumann F.J., Ardissino D., De Servi S., Murphy S.A., Riesmeyer J., Weerakkody G., Gibson C.M., Antman E.M. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
8. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., Horrow J., Husted S., James S., Katus H., Mahaffey K.W., Scirica B.M., Skene A., Steg P.G., Storey R.F., Harrington R.A., Freij A., Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
9. Kinnaird T.D., Stabile E., Mintz G.S., Lee C.W., Canos D.A., Gevorkian N., Pinnow E.E., Kent K.M., Pichard A.D., Satler L.F., Weissman N.J., Lindsay J., Fuchs S. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003, 92:930-935.
10. Rao S.V., O'Grady K., Pieper K.S., Granger C.B., Newby L.K., Mahaffey K.W., Moliterno D.J., Lincoff A.M., Armstrong P.W., Van de Werf F., Califf R.M., Harrington R.A. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006, 47:809-816.
11. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006, 114:774-782.
12. Moscucci M., Fox K.A., Cannon C.P., Klein W., Lopez-Sendon J., Montalescot G., White K., Goldberg R.J. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003, 24:1815-1823.
13. Ben-Dor I., Torguson R., Scheinowitz M., Li Y., Delhaye C., Wakabayashi K., Maluenda G., Syed A.I., Collins S.D., Gonzalez M.A., Gaglia M.A., Xue Z., Kaneshige K., Satler L.F., Suddath W.O., Kent K.M., Pichard A.D., Waksman R. Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. Am Heart J 2010, 159:871-875.
14. Serebruany V.L., Atar D. Assessment of bleeding events in clinical trials-proposal of a new classification. Am J Cardiol 2007, 99:288-290.
15. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008, 52:1128-1133.
16. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908-2913.
17. Bonello L., Tantry U.S., Marcucci R., Blindt R., Angiolillo D.J., Becker R., Bhatt D.L., Cattaneo M., Collet J.P., Cuisset T., Gachet C., Montalescot G., Jennings L.K., Kereiakes D., Sibbing D., Trenk D., Van Werkum J.W., Paganelli F., Price M.J., Waksman R., Gurbel P.A. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010, 56:919-933.
18. Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z., Tantry U.S. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005, 46:1827-1832.
19. Mani H., Luxembourg B., Klaffling C., Erbe M., Lindhoff-Last E. Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements. J Clin Pathol 2005, 58:747-750.
20. Linnemann B., Schwonberg J., Mani H., Prochnow S., Lindhoff-Last E. Standardization of light transmittance aggregometry for monitoring antiplatelet therapy: an adjustment for platelet count is not necessary. J Thromb Haemost 2008, 6:677-683.
21. Patti G., Pasceri V., Vizzi V., Ricottini E., Di Sciascio G. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). Am J Cardiol 2011, 107:995-1000.
22. Sibbing D., Schulz S., Braun S., Morath T., Stegherr J., Mehilli J., Schomig A., von Beckerath N., Kastrati A. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010, 8:250-256.
23. Serebruany V., Rao S.V., Silva M.A., Donovan J.L., Kannan A.O., Makarov L., Goto S., Atar D. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010, 31:227-235.
24. Cuisset T., Cayla G., Frere C., Quilici J., Poyet R., Gaborit B., Bali L., Morange P.E., Alessi M.C., Bonnet J.L. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?. EuroIntervention 2009, 5:325-329.
25. Chen L., Bracey A.W., Radovancevic R., Cooper J.R., Collard C.D., Vaughn W.K., Nussmeier N.A. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J Thorac Cardiovasc Surg 2004, 128:425-431.
26. Poston R., Gu J., Manchio J., Lee A., Brown J., Gammie J., White C., Griffith B.P. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardiothorac Surg 2005, 27:584-591.
27. Ranucci M., Baryshnikova E., Soro G., Ballotta A., De Benedetti D., Conti D. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011, 91:123-129.
28. Rao A., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T., Bell W., Knatterud G., Robertson T., Terrin M. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988, 11:1-11.
29. The GUSTO Investigators An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction. N Engl J Med 1993, 329:673-682.
30. Roy P., Bonello L., Torguson R., de Labriolle A., Lemesle G., Slottow T.L., Steinberg D.H., Kaneshige K., Xue Z., Satler L.F., Kent K.M., Suddath W.O., Pichard A.D., Lindsay J., Waksman R. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol 2008, 102:1614-1617.
31. Price M.J., Berger P.B., Teirstein P.S., Tanguay J.F., Angiolillo D.J., Spriggs D., Puri S., Robbins M., Garratt K.N., Bertrand O.F., Stillablower M.E., Aragon J.R., Kandzari D.E., Stinis C.T., Lee M.S., Manoukian S.V., Cannon C.P., Schork N.J., Topol E.J. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 305:1097-1105.
32. Campo G., Parrinello G., Ferraresi P., Lunghi B., Tebaldi M., Miccoli M., Marchesini J., Bernardi F., Ferrari R., Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011, 57:2474-2483.